

Andreas Ranft

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9300096/publications.pdf>

Version: 2024-02-01

69
papers

2,251
citations

257101

24
h-index

223531

46
g-index

75
all docs

75
docs citations

75
times ranked

2687
citing authors

#	ARTICLE	IF	CITATIONS
1	High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2307-2320.	0.8	24
2	Value of adjuvant radiotherapy in patients with localized Ewing sarcoma at the extremities: Report from the Ewing 2008 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11531-11531.	0.8	0
3	Pain in survivors of Ewing sarcoma: Prevalence, associated factors and prediction of recurrence. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28801.	0.8	1
4	Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Lancet Oncology</i> , The, 2021, 22, e68-e80.	5.1	37
5	Association of treatment delays with an unfavorable outcome in patients with localized Ewing sarcoma: A retrospective analysis of data from the GPOH Euro-E.W.I.N.G.99 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11502-11502.	0.8	3
6	Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. <i>Molecular Cancer</i> , 2021, 20, 97.	7.9	24
7	Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2021, 27, 5922-5930.	3.2	14
8	Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer. <i>Nature Communications</i> , 2021, 12, 5356.	5.8	11
9	Stenotrophomonas maltophilia Infections in Pediatric Patients – Experience at a European Center for Pediatric Hematology and Oncology. <i>Frontiers in Oncology</i> , 2021, 11, 752037.	1.3	10
10	Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing’s Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial. <i>Clinical Orthopaedics and Related Research</i> , 2020, 478, 290-302.	0.7	45
11	Dynamic prediction of overall survival: a retrospective analysis on 979 patients with Ewing sarcoma from the German registry. <i>BMJ Open</i> , 2020, 10, e036376.	0.8	0
12	Fertility education for adolescent cancer patients: Gaps in current clinical practice in Europe. <i>European Journal of Cancer Care</i> , 2020, 29, e13279.	0.7	5
13	Primary and Metastatic Intracranial Ewing Sarcoma at Diagnosis: Retrospective International Study and Systematic Review. <i>Cancers</i> , 2020, 12, 1675.	1.7	8
14	Efficacy of add-on treosulfan and melphalan high-dose therapy in patients with high-risk metastatic Ewing sarcoma: Report from the International Ewing 2008R3 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11501-11501.	0.8	6
15	Efficacy of maintenance therapy with zoledronic acid in patients with localized Ewing sarcoma: Report from the international Ewing 2008 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11523-11523.	0.8	8
16	Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27943.	0.8	17
17	Easy-to-use clinical tool for survival estimation in Ewing sarcoma at diagnosis and after surgery. <i>Scientific Reports</i> , 2019, 9, 11000.	1.6	13
18	Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patients. <i>EBioMedicine</i> , 2019, 47, 156-162.	2.7	23

#	ARTICLE	IF	CITATIONS
19	High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. <i>Journal of Clinical Oncology</i> , 2019, 37, 3192-3202.	0.8	84
20	The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma. <i>Cancer Medicine</i> , 2019, 8, 1086-1094.	1.3	14
21	Recurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage?. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27011.	0.8	22
22	Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92. <i>Clinical Sarcoma Research</i> , 2018, 8, 6.	2.3	19
23	Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information. <i>Modern Pathology</i> , 2018, 31, 1246-1256.	2.9	76
24	High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. <i>Journal of Clinical Oncology</i> , 2018, 36, 3110-3119.	0.8	107
25	Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol. <i>BMC Cancer</i> , 2018, 18, 930.	1.1	13
26	PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents. <i>European Journal of Cancer</i> , 2018, 103, 227-237.	1.3	41
27	Impact of Whole Lung Irradiation on Survival Outcome in Patients With Lung Relapsed Ewing Sarcoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 584-592.	0.4	16
28	Impact of the Interdisciplinary Tumor Board of the Cooperative Ewing Sarcoma Study Group on local therapy and overall survival of Ewing sarcoma patients after induction therapy. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27384.	0.8	22
29	Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27251.	0.8	30
30	T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G. <i>Oncotarget</i> , 2018, 9, 6536-6549.	0.8	37
31	Results for patients with sarcoma not otherwise specified and other diagnoses than Ewing sarcoma treated according to the Euro-EWING 99 trial. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26524.	0.8	4
32	Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells. <i>Oncolmmunology</i> , 2017, 6, e1312239.	2.1	21
33	Ewing sarcoma during follow-up. <i>Nuklearmedizin - NuclearMedicine</i> , 2017, 56, 233-238.	0.3	4
34	Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1704-1712.	0.8	33
35	Long-term outcome of patients with lower extremity Ewing sarcoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 117-117.	0.8	0
36	Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity. <i>Sarcoma</i> , 2016, 2016, 1-6.	0.7	16

#	ARTICLE	IF	CITATIONS
37	Management and Outcome of Ewing Sarcoma of the Head and Neck. <i>Pediatric Blood and Cancer</i> , 2016, 63, 604-610.	0.8	53
38	Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) in localized high-risk Ewing sarcoma (ES): Results of EURO-EWING 99-R2 randomized trial (EE99R2Loc).. <i>Journal of Clinical Oncology</i> , 2016, 34, 11000-11000.	0.8	10
39	Prognostic factors for local control in Ewing sarcoma (ES) in the Euro-EWING99 trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11026-11026.	0.8	2
40	Gene expression profiling of Ewing sarcoma tumours reveals the prognostic importance of tumour-stromal interactions: a report from the Children's Oncology Group. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 83-94.	1.3	66
41	Local Control in Ewing Sarcoma of the Chest Wall: Results of the EURO-EWING 99 Trial. <i>Annals of Surgical Oncology</i> , 2015, 22, 2853-2859.	0.7	39
42	Development of Curative Therapies for Ewing Sarcomas by Interdisciplinary Cooperative Groups in Europe. <i>Klinische Padiatrie</i> , 2015, 227, 108-115.	0.2	9
43	Functional and clinical long-term outcome of Ewing sarcoma treatment*. <i>Journal of Clinical Oncology</i> , 2015, 33, 10529-10529.	0.8	0
44	Abstract 458: Immune-inhibitory HLA-G is expressed in the tumor microenvironment of Ewing Sarcomas. , 2015, , .		0
45	Differentially Expressed miRNAs in Ewing Sarcoma Compared to Mesenchymal Stem Cells: Low miR-31 Expression with Effects on Proliferation and Invasion. <i>PLoS ONE</i> , 2014, 9, e93067.	1.1	34
46	The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1382-1386.	0.8	52
47	Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 2440-2448.	0.8	136
48	Long-term follow-up of the CESS 81 and CESS 86 Ewing sarcoma trials.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10529-10529.	0.8	0
49	Abstract A72: Do prognostic gene signatures exist in Ewing sarcoma? A report from the Children's Oncology Group. , 2014, , .		0
50	Renal Ewing tumors. <i>Annals of Oncology</i> , 2013, 24, 2455-2461.	0.6	35
51	Impact of gender on efficacy and acute toxicity in standard risk localized (SR) Ewing sarcomas (ES) in the Euro-Ewing99-R1 trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10031-10031.	0.8	1
52	High STEAP1 expression is associated with improved outcome of Ewing's sarcoma patients. <i>Annals of Oncology</i> , 2012, 23, 2185-2190.	0.6	43
53	Ewing Sarcoma of the Hand or Foot. <i>Klinische Padiatrie</i> , 2012, 224, 348-352.	0.2	7
54	Risk of recurrence and survival after relapse in patients with Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2011, 57, 549-553.	0.8	228

#	ARTICLE	IF	CITATIONS
55	The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). <i>Cancer</i> , 2010, 116, 443-450.	2.0	137
56	Impact of <i>EWS-ETS</i> Fusion Type on Disease Progression in Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor: Prospective Results From the Cooperative Euro-E.W.I.N.G. 99 Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 1982-1988.	0.8	180
57	Ewing sarcoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 2010, 28, e20516-e20516.	0.8	1
58	A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25 ^{hi} FoxP3+) in Ewing sarcoma patients is associated with metastatic disease. <i>International Journal of Cancer</i> , 2009, 125, 879-886.	2.3	51
59	Radiation Toxicity Following Busulfan/Melphalan High-dose Chemotherapy in the EURO-EWING-99-trial: Review of GPOH Data. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 21-22.	1.0	32
60	Treosulfan-based high-dose chemotherapy with autologous stem cell transplantation in high-risk Ewing sarcoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 10546-10546.	0.8	4
61	Whole Lung Irradiation in Patients with Exclusively Pulmonary Metastases of Ewing Tumors. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 193-197.	1.0	72
62	Ewing tumors in infants. <i>Pediatric Blood and Cancer</i> , 2008, 50, 761-764.	0.8	20
63	Ewing's Tumors over the Age of 40 – a Retrospective Analysis of 47 Patients Treated According to the International Clinical Trials EICESS 92 and EURO-E.W.I.N.G. 99. <i>Oncology Research and Treatment</i> , 2008, 31, 657-663.	0.8	22
64	Treatment evolution in localized Ewing tumors of the pelvis and femur. <i>Journal of Clinical Oncology</i> , 2008, 26, 10513-10513.	0.8	0
65	Ewing tumours: Outcome in children, adolescents and adult patients. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 209-215.	2.2	6
66	Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 749-759.	1.2	22
67	Risks of recurrence and survival after relapse in patients with Ewing tumor. <i>Journal of Clinical Oncology</i> , 2007, 25, 10012-10012.	0.8	2
68	Bone Marrow T Cell Subpopulations in Patients with Newly Diagnosed B-Cell Precursor Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2007, 110, 4278-4278.	0.6	7
69	Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. <i>Pediatric Blood and Cancer</i> , 2006, 47, 795-800.	0.8	148